Flemington, NJ, United States of America

Virginia L Pulito

USPTO Granted Patents = 10 

Average Co-Inventor Count = 4.9

ph-index = 2

Forward Citations = 17(Granted Patents)


Company Filing History:


Years Active: 2000-2010

Loading Chart...
10 patents (USPTO):Explore Patents

Title: Virginia L Pulito: Innovator in Anticoagulant Antibodies

Introduction

Virginia L Pulito is a prominent inventor based in Flemington, NJ (US). She has made significant contributions to the field of biomedical research, particularly in the development of innovative antibodies for therapeutic use. With a total of 10 patents, her work has had a profound impact on the treatment of thrombotic diseases.

Latest Patents

Among her latest inventions are the CDR-grafted anti-tissue factor antibodies and methods of use thereof. This invention provides CDR-grafted antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also includes methods of making the CDR-grafted antibodies and pharmaceutical compositions for the attenuation or prevention of coagulation.

Career Highlights

Virginia has worked with notable companies such as Ortho-McNeil Pharmaceutical Corporation and Janssen Pharmaceutica NV. Her experience in these organizations has allowed her to develop and refine her innovative ideas in the pharmaceutical industry.

Collaborations

Throughout her career, Virginia has collaborated with esteemed colleagues, including George Chiu and Peter J Connolly. These partnerships have contributed to her success and the advancement of her research.

Conclusion

Virginia L Pulito is a trailblazer in the field of anticoagulant antibodies, with a strong portfolio of patents that reflect her innovative spirit and dedication to improving human health. Her contributions continue to influence the development of effective treatments for thrombotic diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…